Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder

NCT02288325 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT02288325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02288325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder
Lead sponsor
Forest Laboratories
Phase
Phase 4
Overall status
Completed
Start date
November 18, 2014
Completion date
September 16, 2016
Enrollment
644 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major